COMPASS Pathways Plc · NASDAQ:CMPS
COMPASS Pathways — Investor Presentation (January 2025)
15 slides from COMPASS Pathways's investor presentation, January 2025
Slide 1: Transforming Mental Health Care
Transforming Mental Health Care Investor Presentation January 2025
Slide 2: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terms such as “believe,” “cont
Slide 3: Compass Pathways
Compass Pathways Dedicated to accelerating patient access to evidence-based innovation in mental health. – Lead product candidate: COMP360 psilocybin treatment in treatment resistant depression (TRD) – Phase 2 TRD program published in The New England Journal of Medicine Phase 3 TRD program recruitin
Slide 4: TRD treatment pathway: significant unmet need for 100 million patients
TRD treatment pathway: significant unmet need for 100 million patients New onset depression Persistent depression Treatment-resistant Treatment pathway stage Major depressive disorder Major depressive disorder depression (TRD) (MDD) (MDD) Line of therapy First line Second line Third line + 100 milli
Slide 5: Phase 3 program: Overview of ongoing pivotal trial designs
Phase 3 program: Overview of ongoing pivotal trial designs Week 6 (Part A) Primary endpoint* Randomisation = 2:1 COMP360 Pivotal trial 1 25 mg n = 255 (170:85) Long- Single dose term monotherapy follow-up Top line 6-week data expected (COMP 005) Placebo Q2 2025 Week 6 (Part A) Week 3 Primary endpoin
Slide 6: Phase 3 program long-term follow up component
Phase 3 program long-term follow up component Part A (blinded): Part B (blinded): Part C (open label): Week 6 to week 26 week 26 to week 52 primary endpoint* COMP360 pivotal 25 mg option for trial 1 retreatment COMP360 25mg treatment (005) (same dose (after relapse) n=255 as Part A) Placebo COMP360
Slide 7: Phase 2b trial: Results demonstrate the potential for a rapid, sustained response in TRD
Phase 2b trial: Results demonstrate the potential Published in The NEW ENGLAND JOURNAL of MEDICINE* for a rapid, sustained response in TRD Randomized, controlled, double-blind trial, 3 arms, single dose (either 1mg, 10mg or 25 mg) of COMP360 psilocybin alongside psychological support. Results were m
Slide 8: Phase 2b most frequent TEAEs ordered by the 25mg arm
Phase 2b most frequent TEAEs ordered by the 25mg arm (at least 5% in any treatment group) TEAE incidence is COMP360 COMP360 COMP360 higher in the 25mg Overall 25mg 10mg 1mg group overall MedDRA TEAE preferred term N=79 N=75 N=79 N=233 n (%) Key mood-related Headache 27 (34.2) 16 (21.3) 20 (25.3) 63
Slide 9: Phase 2b trial: COMP360 psilocybin treatment was generally well-tolerated
Phase 2b trial: COMP360 psilocybin treatment was generally well-tolerated Treatment-emergent adverse events There were no concerns with vital signs, ECG or clinical (TEAEs) laboratory data in any of the treatment groups >90% TEAEs involving hallucinations (which only occurred in the of TEAEs were of
Slide 10: Preparing for scale at launch, if approved
Preparing for scale at launch, if approved Compass Pathways intends to deliver COMP360 (medicine) to Treatment Centers through specialty pharmacy channels, reimbursed by Payers Payers/specialty Treatment pharmacy Centers Our strategy for reimbursement is for Treatment Centers to be reimbursed by Pay
Slide 11: The infrastructure to deliver COMP360 psilocybin treatment already exists and is growing
The infrastructure to deliver COMP360 psilocybin treatment already exists and is growing Specialty TRD centers, health systems, and integrated delivery networks (IDNs), some of which are clinical trial sites during our phase TMS: 3 clinical program, are already experienced 30-36 treatments(2)(5) in
Slide 12: We are developing a balanced and differentiated pipeline
We are developing a balanced and differentiated pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved Lead COMP360 program in TRD COMP360 for TRD Beyond TRD: We’re assessing the safety and efficacy of COMP360 for PTSD COMP360 psilocybin therapy for PTSD and anorexia COMP360 for anorexia ne
Slide 13: Post-traumatic stress disorder (PTSD) positive phase 2 study
Post-traumatic stress disorder (PTSD) positive phase 2 study Summary of change from baseline in CAPS-5 score ➢ N=22, multi-center open-label, single administration of 25mg COMP360 with psychological support ➢ Early onset and sustained change from baseline in CAPS-5 observed at week 4 and week 12 ➢ D
Slide 14: Phase 2 PTSD study safety profile
Phase 2 PTSD study safety profile (primary endpoint) Summary of most frequent TEAES (≥10% prevalence) COMP360 was well tolerated with no treatment emergent serious adverse events reported No participants re-started SSRI’s or antidepressants after COMP360 administration in study There were 2 events o
Slide 15: We're a biotechnology company…
We're a biotechnology company… …dedicated to accelerating patient access to evidence-based innovation in mental health. Stephen Schultz SVP, Investor Relations stephen.schultz@compasspathways.com +1 401-290-7324 15 | © Compass Pathways
COMPASS Pathways — Investor Presentation (January 2025) on 6ix